The Tufts Center for the Study of Drug Development (Tufts CSDD) is an independent, academic non-profit research center affiliated with Tufts University School of Medicine in Boston, Massachusetts. Founded in 1976 by pharmacologist Louis Lasagna, it analyzes the performance, efficiency, and economics of pharmaceutical and biotechnology drug development.
Tufts CSDD conducts 15-20 grant-funded studies annually across platforms including drug development economics, clinical trial design and execution, manufacturing logistics, and regulatory affairs. It maintains proprietary databases on investigational and approved drugs, publishes Impact Reports, peer-reviewed articles, and white papers, and offers benchmarking and optimization services to industry stakeholders.
Funded roughly equally by public and private sector grants, the center provides data-driven insights to pharmaceutical companies, regulators, and policymakers, with notable research on drug development costs and timelines.
None yet. When a new project in the record names Tufts CSDD as owner, partner or investor, it shows here.
Selected via client evaluations and Tufts CSDD, praised for specialized staff, cultural fit, tech use and scaling support; offers cGMP CDMO services across Japan, US, EU and supports varied modalities
